Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors

Why testing for TP53, del(17q), and IGHV status critical for treatment selection and outcome optimization. Here’s my take.

Danielle Brander, MD Released: September 22, 2020

The implications of minimal residual disease status on treatment of CLL is evolving. Here’s my take on what you should know now.

Danielle Brander, MD Released: September 29, 2020

Get the latest information on how investigational noncovalent BTK inhibitors, such as LOXO-305 and ARQ 531, may help treat patients with CLL and resistance to currently available BTK inhibitors.

Jeff P. Sharman, MD Released: September 25, 2020